ZA201701946B - Fused pentacyclic imidazole derivatives - Google Patents

Fused pentacyclic imidazole derivatives

Info

Publication number
ZA201701946B
ZA201701946B ZA2017/01946A ZA201701946A ZA201701946B ZA 201701946 B ZA201701946 B ZA 201701946B ZA 2017/01946 A ZA2017/01946 A ZA 2017/01946A ZA 201701946 A ZA201701946 A ZA 201701946A ZA 201701946 B ZA201701946 B ZA 201701946B
Authority
ZA
South Africa
Prior art keywords
imidazole derivatives
fused pentacyclic
pentacyclic imidazole
fused
derivatives
Prior art date
Application number
ZA2017/01946A
Other languages
English (en)
Inventor
Filoche-Romme Bruno
Foricher Yann
Schio Laurent
Louis Léon Swinnen Dominique
Alan Shaw Michael
Duncan Selby Matthew
Mac Coss Malcolm
Keyaerts Jean
Jadot Sophie
Andrew Johnson James
Clive Hutchings Martin
Evrard Yves
Daniel Calmiano Mark
Christopher Brookings Daniel
Zhu Zhaoning
Xuan Mengyang
Rachel Quincey Joanna
Paul Heer Jag
Deligny Michael
De Haro Garcia Teresa
Original Assignee
Sanofi A French Sa
Ucb Biopharma Sprl A Company Organised And Existing Under The Laws Of Belgium
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi A French Sa, Ucb Biopharma Sprl A Company Organised And Existing Under The Laws Of Belgium filed Critical Sanofi A French Sa
Publication of ZA201701946B publication Critical patent/ZA201701946B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA2017/01946A 2014-10-03 2017-03-20 Fused pentacyclic imidazole derivatives ZA201701946B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14290299 2014-10-03
EP15162641 2015-04-07
EP15171036 2015-06-08
PCT/EP2015/072868 WO2016050975A1 (en) 2014-10-03 2015-10-02 Fused pentacyclic imidazole derivatives

Publications (1)

Publication Number Publication Date
ZA201701946B true ZA201701946B (en) 2018-07-25

Family

ID=54238452

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/01946A ZA201701946B (en) 2014-10-03 2017-03-20 Fused pentacyclic imidazole derivatives

Country Status (36)

Country Link
US (3) US10202405B2 (en:Method)
EP (1) EP3201196B1 (en:Method)
JP (1) JP6629847B2 (en:Method)
KR (1) KR102442235B1 (en:Method)
CN (1) CN107108672B (en:Method)
AP (1) AP2017009809A0 (en:Method)
AU (1) AU2015326798B2 (en:Method)
BR (1) BR112017006669B1 (en:Method)
CA (1) CA2962826C (en:Method)
CL (1) CL2017000787A1 (en:Method)
CO (1) CO2017003331A2 (en:Method)
CR (1) CR20170167A (en:Method)
DK (1) DK3201196T3 (en:Method)
EA (1) EA032839B1 (en:Method)
EC (1) ECSP17027306A (en:Method)
ES (1) ES2885432T3 (en:Method)
GT (1) GT201700044A (en:Method)
HR (1) HRP20211605T1 (en:Method)
HU (1) HUE056133T2 (en:Method)
IL (1) IL251147B (en:Method)
LT (1) LT3201196T (en:Method)
MA (1) MA40770B1 (en:Method)
MX (1) MX380578B (en:Method)
MY (1) MY181019A (en:Method)
PE (1) PE20170693A1 (en:Method)
PH (1) PH12017500414B1 (en:Method)
PL (1) PL3201196T3 (en:Method)
RS (1) RS62423B1 (en:Method)
SG (1) SG11201701796XA (en:Method)
SI (1) SI3201196T1 (en:Method)
TN (1) TN2017000083A1 (en:Method)
TW (1) TWI719949B (en:Method)
UA (1) UA120764C2 (en:Method)
UY (1) UY36341A (en:Method)
WO (1) WO2016050975A1 (en:Method)
ZA (1) ZA201701946B (en:Method)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102442235B1 (ko) * 2014-10-03 2022-09-08 유씨비 바이오파마 에스알엘 융합된 펜타시클릭 이미다졸 유도체
WO2016168641A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Tricyclic modulators of tnf signaling
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
US20160304496A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
JP6968092B2 (ja) * 2016-04-01 2021-11-17 ユーシービー バイオファルマ エスアールエル Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
US10654861B2 (en) 2016-04-01 2020-05-19 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of TNF activity
CA3018992A1 (en) * 2016-04-01 2017-10-05 Ucb Biopharma Sprl Fused hexacyclic imidazole derivatives as modulators of tnf activity
WO2017167996A1 (en) 2016-04-01 2017-10-05 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives as modulators of tnf activity
GB201620948D0 (en) 2016-12-09 2017-01-25 Ucb Biopharma Sprl Therapeutic agents
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
US10953019B2 (en) 2017-03-15 2021-03-23 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of TNF activity
WO2018197503A1 (en) * 2017-04-25 2018-11-01 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives as modulators of tnf activity
AR114465A1 (es) * 2018-04-04 2020-09-09 Japan Tobacco Inc Compuestos de pirazol sustituidos con heteroarilo y su utilización farmacéutica
WO2020084008A1 (en) 2018-10-24 2020-04-30 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of tnf activity
CN113683505A (zh) * 2021-09-29 2021-11-23 厦门大华本安化工安全研究院有限公司 一种含氧代环丁基的羧酸酯类化合物的制备方法
KR20250112837A (ko) * 2022-11-23 2025-07-24 포워드 테라퓨틱스, 인코포레이티드 TNF-α 활성의 조절제
WO2024129763A1 (en) * 2022-12-13 2024-06-20 Forward Therapeutics, Inc. MODULATORS OF TNF-α ACTIVITY
WO2024148191A1 (en) * 2023-01-05 2024-07-11 Forward Therapeutics, Inc. MODULATORS OF TNF-α ACTIVITY
KR20260004440A (ko) 2023-04-26 2026-01-08 사노피 종양 괴사 인자 알파의 소분자 저해제를 사용한 건선 치료
CN121399133A (zh) * 2023-06-09 2026-01-23 上海翰森生物医药科技有限公司 五环类衍生物抑制剂、其制备方法和应用
CN119630670A (zh) * 2023-08-16 2025-03-14 瑞雷拉公司 TNFα活性调节剂及其用途
WO2025068505A1 (en) 2023-09-29 2025-04-03 Sanofi Preparation of bridged pentacyclic imidazole derivatives as modulators of tnf activity, intermeditates and their preparation
WO2025137267A1 (en) * 2023-12-21 2025-06-26 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2025201449A1 (zh) * 2024-03-27 2025-10-02 海思科医药集团股份有限公司 一种杂环衍生物及其在医药上的应用
WO2025212627A1 (en) 2024-04-03 2025-10-09 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2025218735A1 (zh) * 2024-04-17 2025-10-23 上海翰森生物医药科技有限公司 五环类衍生物抑制剂、其制备方法和应用
WO2025244936A1 (en) * 2024-05-20 2025-11-27 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2025247401A1 (zh) * 2024-05-31 2025-12-04 海思科医药集团股份有限公司 一种稠合杂环衍生物及其在医药上的应用
WO2025255096A1 (en) * 2024-06-03 2025-12-11 Dana-Farber Cancer Institute, Inc. Cycloalkyl and heterocyclic modulators of tnf activity
WO2025252251A1 (zh) * 2024-06-07 2025-12-11 上海翰森生物医药科技有限公司 含氧杂环类衍生物抑制剂、其制备方法和应用
WO2026022134A1 (en) 2024-07-23 2026-01-29 Sanofi Novel aminocarbonylation processes
WO2026021586A1 (zh) * 2024-07-26 2026-01-29 上海瀚辰星泰医药科技有限公司 一种多环化合物及其制备方法和应用
WO2026027449A1 (en) 2024-07-29 2026-02-05 Sanofi Fused pentacyclic imidazole derivatives

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449649A3 (en) 1990-03-30 1992-09-02 Arizona Board Of Regents, Arizona State University Antineoplastic quinones and methods of using same
FR2832711B1 (fr) 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
EP1603926A1 (en) 2003-03-10 2005-12-14 Pfizer Inc. Phosphate/sulfate ester compounds and pharmaceutical compositions for inhibiting protein interacting nima (pin1)
DE102008030206A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
WO2012177707A1 (en) 2011-06-20 2012-12-27 Vertex Pharmaceuticals Incorporated Phosphate esters of gyrase and topoisomerase inhibitors
CA2874303C (en) * 2012-06-11 2020-10-13 Ucb Biopharma Sprl Tnf -alpha modulating benz imidazoles
EA028722B1 (ru) 2012-07-13 2017-12-29 Юсб Байофарма Спрл Производные имидазопиридина в качестве модуляторов активности tnf
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
CA2927252C (en) 2013-10-25 2021-09-28 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
HUE039062T2 (hu) 2014-04-15 2018-12-28 Vertex Pharma Gyógyszerészeti készítmények cisztás fibrózis transzmembrán konduktancia regulátor által mediált betegségek kezelésére
KR102442235B1 (ko) * 2014-10-03 2022-09-08 유씨비 바이오파마 에스알엘 융합된 펜타시클릭 이미다졸 유도체

Also Published As

Publication number Publication date
JP2017531648A (ja) 2017-10-26
BR112017006669A2 (pt) 2017-12-26
MY181019A (en) 2020-12-16
ES2885432T3 (es) 2021-12-13
US20170305932A1 (en) 2017-10-26
KR20170068503A (ko) 2017-06-19
MA40770A (fr) 2021-03-24
US20210155637A1 (en) 2021-05-27
PH12017500414B1 (en) 2021-09-10
MA40770B1 (fr) 2021-11-30
UY36341A (es) 2016-04-29
CA2962826A1 (en) 2016-04-07
PE20170693A1 (es) 2017-06-13
LT3201196T (lt) 2021-09-27
IL251147A0 (en) 2017-04-30
MX380578B (es) 2025-03-12
TWI719949B (zh) 2021-03-01
PH12017500414A1 (en) 2017-07-17
EA201790734A1 (ru) 2017-09-29
AP2017009809A0 (en) 2017-03-31
US20190367535A1 (en) 2019-12-05
RS62423B1 (sr) 2021-10-29
KR102442235B1 (ko) 2022-09-08
HUE056133T2 (hu) 2022-01-28
WO2016050975A1 (en) 2016-04-07
UA120764C2 (uk) 2020-02-10
US11912721B2 (en) 2024-02-27
SI3201196T1 (sl) 2021-12-31
SG11201701796XA (en) 2017-04-27
IL251147B (en) 2020-05-31
EA032839B1 (ru) 2019-07-31
TN2017000083A1 (en) 2018-07-04
PL3201196T3 (pl) 2022-01-03
ECSP17027306A (es) 2017-05-31
US10202405B2 (en) 2019-02-12
AU2015326798B2 (en) 2020-01-02
CR20170167A (es) 2017-08-10
US10906919B2 (en) 2021-02-02
DK3201196T3 (da) 2021-09-06
CN107108672B (zh) 2019-11-08
MX2017004201A (es) 2017-05-30
CO2017003331A2 (es) 2017-09-29
EP3201196B1 (en) 2021-07-28
CL2017000787A1 (es) 2017-11-24
CN107108672A (zh) 2017-08-29
NZ730256A (en) 2021-05-28
HRP20211605T1 (hr) 2022-01-21
EP3201196A1 (en) 2017-08-09
BR112017006669B1 (pt) 2023-04-18
AU2015326798A1 (en) 2017-04-06
JP6629847B2 (ja) 2020-01-15
TW201629067A (zh) 2016-08-16
GT201700044A (es) 2019-09-09
CA2962826C (en) 2023-08-08

Similar Documents

Publication Publication Date Title
ZA201701946B (en) Fused pentacyclic imidazole derivatives
IL291598A (en) History of benzodiazepine cytotoxicity
IL253381B (en) History of h9–pyrrolo–dipyridine
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
PL3164393T3 (pl) Pochodne flawaglin
EP3099672A4 (en) Fused imidazole compounds
HUE050450T2 (hu) Fluoralkil-fluorén-származékok
IL248773A0 (en) History of naphthyridinedione
IL251005B (en) Pyrido-oxazinone derivatives
ZA201605243B (en) Ethynyl derivatives
SG11201608634RA (en) Cycloalkyl-linked diheterocycle derivatives
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
GB201414116D0 (en) Benzodiazepine derivatives
PL3228616T3 (pl) Pochodne pirydyny
GB201416351D0 (en) Heterocyclic derivatives
PT3201196T (pt) Derivados de imidazol pentacíclicos fusionados